CME/CE

Host: Darren Brenner, MD Irritable bowel syndrome with constipation (IBS-C) significantly impacts patients, not only with its physical symptoms of persistent constipation, abdominal pain, and bloating, but also through a considerable psychological and social burden. Do you know how to effectively treat IBS-C to increase your patients’ quality of life? Tune in for an overview of the latest data.

Guest: Kenneth Lieberman, MD Guest: Howard Trachtman, MD, FASN Focal segmental glomerulosclerosis (FSGS) is a prominent cause of kidney failure globally, necessitating dialysis for patient survival as the disease progresses. However, the current absence of FDA-approved treatments tailored specifically for treating adult and pediatric patients with FSGS poses a significant challenge to effectively managing this disease. Moreover, it is imperative for nephrologists to enhance their skills to implement practical strategies that improve the diagnostic approach for suspected FSGS cases, especially considering the profound impact of FSGS on patients' quality of life. This activity has been designed to provide practical guidance for the accurate diagnosis of FSGS and appropriate treatment selection, as well as to offer an expert assessment of the clinical trial data supporting emerging therapies in this setting.

Guest: Børge G. Nordestgaard, MD, DMSc Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Pam R. Taub, MD, FACC, FASPC Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Pam R. Taub, MD, FACC, FASPC Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Daniel Gaudet, MD, PhD Guest: Pam R. Taub, MD, FACC, FASPC There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Pam R. Taub, MD, FACC, FASPC Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Børge G. Nordestgaard, MD, DMSc Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Pam R. Taub, MD, FACC, FASPC Guest: Prof. Kausik Ray There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Børge G. Nordestgaard, MD, DMSc Guest: Kausik Ray, MBChB, MD, MPhil There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

Guest: Daniel Gaudet, MD, PhD There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

Guest: Neal Shore, MD, FACS Guest: Sarah Psutka, MD, MS This online CME program features expert discussions on new research presented at AUA 2025. Drs. Neal Shore and Sarah Psutka explore emerging data on treatment strategies for high-risk BCG-naïve and BCG-unresponsive non–muscle invasive bladder cancer (NMIBC). They also highlight advances in biomarker-directed therapies, including investigational agents targeting HER2 and FGFR alterations. The program emphasizes the clinical relevance and practical application of these findings, offering clinicians actionable insights on evolving bladder cancer care.

Host: Fernanda P. Silveira, MD, MS, FIDSA, FAST Guest: Jennifer Saullo, MD, PharmD, FIDSA Join experts, Fernanda P. Silveira, MD, MS, FIDSA, FAST and Jennifer Saullo, MD, PharmD, FIDSA, as they delve into the complexities of cytomegalovirus (CMV) prevention and treatment following solid organ transplantation (SOT). Presentations will feature detailed case discussions with a focus on managing resistant and refractory disease, addressing treatment-related toxicities, and optimizing therapeutic strategies. This program is an essential primer on the scientific challenges and solutions in this critical area of transplant medicine.

Guest: Pedro Barata, MD, MSc, FACP Guest: Sumanta K. Pal, MD, FASCO Stay at the forefront of nccRCC care by exploring the latest advances in treatment strategies. Gain key insights into optimizing patient selection, enhancing diagnostic accuracy, and managing adverse events to improve patient outcomes. This comprehensive activity delves into emerging data, the rationale for ICI/TKI combination therapy, the latest clinical trial findings, and best practices for treatment sequencing. Take action today to refine your approach and deliver the best possible care for your patients.

Host: Crystal Proud, MD Guest: John Brandsema, MD Guest: Omer Abdul Hamid, MD Explore the latest treatment options, age-specific management strategies, and clinical trial data for patients with Duchenne muscular dystrophy (DMD). Through expert-led discussions and real-world patient cases, you’ll gain practical insights to help you confidently navigate today’s ever-evolving treatment landscape and deliver personalized, informed care.